March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Dexamethasone Intravitreal Implant (Ozurdex®) in Treatment of Refractory Macular Edema
Author Affiliations & Notes
  • Nir Sorkin
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Michaella Goldstein
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Adiel Barak
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Elad Moisseiev
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Anat Loewenstein
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships  Nir Sorkin, None; Michaella Goldstein, Lecture Fees from Novartis & Allergan (R); Adiel Barak, Neovista research grant (F), Orabio, BiolineRX (C); Elad Moisseiev, None; Anat Loewenstein, Allergan, ForsightLabs, Lumenis, Notal Vision, Novartis, Orabio (C), Novartis advisory board member (S)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 903. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nir Sorkin, Michaella Goldstein, Adiel Barak, Elad Moisseiev, Anat Loewenstein; Dexamethasone Intravitreal Implant (Ozurdex®) in Treatment of Refractory Macular Edema. Invest. Ophthalmol. Vis. Sci. 2012;53(14):903.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA) in the treatment of refractory cystoid macular edema (CME).

Methods: : A consecutive clinical series follow-up of patients with refractory CME, treated in our clinic between August 2010 and October 2011, using a sustained-release dexamethasone 0.7 mg intravitreal implant (Ozurdex®). All patients were previously treated (by one or more of: focal/grid laser, anti-VEGF injections, Triamcinolone). Follow-up included a complete ophthalmic examination including visual acuity, intraocular pressure measurements and a funduscopic evaluation, supplemented by Optical Coherence Tomography (OCT), and fluorescein angiography as necessary.

Results: : Twenty two eyes of 20 patients were treated with a total of 29 Ozurdex® injections. Fifteen of the 22 eyes had completed a follow-up period of ≥15 weeks, and are included in this report (15 eyes, 13 patients, 18 injections). Mean follow-up time was 19.2 weeks (range 15-26 weeks). The mean baseline Central Macular Thickness (CMT) was 592μ (331-846μ). Fifteen of the 18 implant injections achieved a decrease in CMT of more than 100 micron at any point throughout the follow-up. The mean logMAR baseline BCVA was 0.64. Ten of the 18 implant injections led to an improvement in logMAR BCVA of 0.1 or more throughout the follow-up. Throughout the entire follow-up period, 3 measurements of intraocular pressure (IOP) above 25 mmHg were recorded in 2 patients (range 27-30 mmHg), normalized under topical medications. No adverse post-injection effects were documented.

Conclusions: : Intravitreal injection of the Ozurdex® implant should be considered as a treatment option in patients with CME. Its effect on CMT and VA appears to be maximal 9-10 weeks after injection. The treatment safety profile was excellent.

Keywords: macula/fovea • edema 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×